Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Research Notes

Open Access

Spatial profiles of markers of glycolysis, mitochondria, and proton pumps in a rat glioma suggest coordinated programming for proliferation

  • Emmanuelle Grillon1, 2, 3, 4,
  • Régine Farion1, 2, 3, 4,
  • Moshe Reuveni5,
  • Andrew Glidle6,
  • Chantal Rémy1, 7 and
  • Jonathan A. Coles8Email author
BMC Research Notes20158:207

https://doi.org/10.1186/s13104-015-1191-z

Received: 5 March 2015

Accepted: 20 May 2015

Published: 2 June 2015

Abstract

Background

In cancer cells in vitro, the glycolytic pathway and the mitochondrial tricarboxylic acid (TCA) cycle are programmed to produce more precursor molecules, and relatively less ATP, than in differentiated cells. We address the questions of whether and where these changes occur in vivo in glioblastomas grown from C6 cells in rat brain. These gliomas show some spatial organization, notably in the upregulation of membrane proton transporters near the rim.

Results

We immunolabeled pairs of proteins (as well as DNA) on sections of rat brains containing gliomas, measured the profiles of fluorescence intensity on strips 200 µm wide and at least 3 mm long running perpendicular to the tumor rim, and expressed the intensity in the glioma relative to that outside. On averaged profiles, labeling of a marker of the glycolytic pathway, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was, as expected, greater in the glioma. Over distances up to 2.5 mm into the glioma, expression of a marker of the TCA cycle, Tom20, a pre-protein receptor on the translocation complex of the mitochondrial outer membrane, was also upregulated. The ratio of upregulation of Tom20 to upregulation of GAPDH was, on average, slightly greater than one. Near the rim (0.4–0.8 mm), GAPDH was expressed less and there was a peak in the mean ratio of 1.16, SEM = 0.001, N = 16 pairs of profiles. An antibody to V-ATPase, which, by pumping protons into vacuoles contributes to cell growth, also indicated upregulation by about 40%. When compared directly with GAPDH, upregulation of V-ATPase was only 0.764, SD = 0.016 of GAPDH upregulation.

Conclusions

Although there was considerable variation between individual measured profiles, on average, markers of the glycolytic pathway, of mitochondria, and of cell proliferation showed coherent upregulation in C6 gliomas. There is a zone, close to the rim, where mitochondrial presence is upregulated more than the glycolytic pathway, in agreement with earlier suggestions that lactate is taken up by cells near the rim.

Keywords

GlioblastomaGlycolysisMitochondriaV-ATPaseSpatial structureC6 gliomaRatGAPDHTom20Immunofluorescence

Background

Glioblastomas, which derive from the astrocyte lineage and are almost invariably fatal, are among that majority of cancers initiated by stochastic errors of DNA replication and not caused by genetic predisposition or environmental carcinogens [1]. Surgical resection, conventional radiation therapy and anti-angiogenic chemotherapy [2] have had only limited success in their treatment. Hence new therapies are required and their development might benefit from a better understanding of the physiology. Although there is considerable variety in the molecular phenotypes of human glioblastomas [3], the more malignant ones colonize the brain by growth of the tumor mass and by migration of individual cells away from the tumor rim [47], so we focus here on the rim.

The tumor grown in Wistar rat brain from the C6 cell line of transformed rat astrocytes colonizes the brain in a manner similar to many human glioblastomas [810]. By analyzing the distribution of antibodies to marker molecules on tissue sections, we have previously shown that the rim of a C6 glioma shows a degree of organization that is statistically significant when several spatial profiles are averaged. Notably, expression of the membrane Na+/H+ exchanger, NHE1 (SLC9A12), which contributes to cell migration by extruding protons [1117] and interacting with the cytoskeleton [12, 18], is upregulated in a peak at the rim [19]. The internal H+ binding site of NHE1 is modified in cancer cells so that NHE1 continues to export protons even when the intracellular pH (pHi) rises higher than in normal cells [11, 12, 2023]. The exported protons contribute to lowering extracellular pH (pHe) below the normal 7.3, and this acidic pHe assists invasion of host tissue by killing differentiated cells [24] and by activating metallo matrix proteases, which break down extracellular matrix and facilitate cell migration into host tissue [12, 25, 26].

The export of protons on NHE1 is intimately dependent on energy metabolism, since Na+/H+ exchangers require an inward gradient of [Na+], which is maintained by the ATP-consuming Na+ pump (or Na+-K+ ATPase). In differentiated cells, nearly all the ATP is produced by oxidative phosphorylation associated with the TCA cycle in mitochondria, the mitochondria being fuelled by pyruvate produced by the Embden-Meyerhof glycolytic pathway. In cancer cells, and other proliferating cells in culture, the glycolytic pathway and the TCA cycle are reprogrammed to produce intermediates necessary for the synthesis of the macromolecules of cell growth, rather than a maximum of ATP [2731]. As part of this reprogramming, much of the pyruvate is converted to lactate, and tumors show a net excretion of lactate [3234]. Lactate export (and import) is mediated by members of the monocarboyxlate transporter (MCT) family. In some tumors, including C6 gliomas, expression of the lactate transporter MCT1 is upregulated near the tumor rim [19, 35] an arrangement which has led to the hypothesis that some of the lactate produced deeper in a tumor diffuses towards the rim where it is taken up and oxidized [19, 3537]. If this is true, then the ratio of oxidative phosphorylation to glycolysis in the rim might be greater than in the bulk of the tumor, and one aim of the present work is to see if there is evidence for this.

Also involved in both cell metabolism and the creation of an acidic pHe is the vacuolar H+-ATPase (V-ATPase), a proton pump. In addition to being a consumer of ATP [3840], V-ATPase contributes to the metabolism of proliferating cells by transporting H+ into vacuoles (including endosomes, lysosomes and the Golgi apparatus) that are the sites of synthesis and degradation of macromolecules [3942]. Upregulation of V-ATPase in cancer cell lines is associated with increased invasiveness [40, 43, 44] and V-ATPase has repeatedly been proposed as a target for cancer therapy [4550]. In C6 cells, it is present on the plasma membrane [51] as well as vacuoles [43, 52]. It would be interesting to know how upregulated expression of V-ATPase compares with expression of the Embdem-Meyerhof pathway and this is the second question we address.

Nearly all of the extensive work on cancer metabolism and signaling has been done on cells in culture (see, e.g. [30, 5355]); our aim here is to complement this with a description of spatial organization in a tumor. The mean distances from the rim to the peaks of NHE1 and MCT1 in C6 gliomas have been measured as 0.33 and 1.05 mm, respectively [19]. To obtain comparable spatial profiles (with resolution <10 µm over distances of millimeters), we tile-scanned tissue sections labeled with antibodies to marker molecules, and measured intensity profiles along strips perpendicular to the glioma rim, as previously [19]. Intensities were normalized with respect to the host tissue and a number of profiles from different sections were aligned and averaged (see “Methods”). The choice of markers was more limited than for cells in culture (for example, the mitochondrial label MitoTracker does not work on dead tissue), and we concentrated on obtaining statistically significant results for three markers. We used antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a marker of the glycolytic pathway, Tom20, a receptor for pre-proteins that forms part of the translocase complex of the outer mitochondrial membrane [56, 57], and V-ATPase.

Methods

Ethics statement

All procedures involving animals conformed to European Council Directive 2010/63/UE and the study was approved by the Ethical Committee of the Grenoble-Institut des Neurosciences, agreement ID 004. Facilities for animal housing and procedures were approved by the French Ministry of Agriculture, licence B 38 516 10008 and all experimenters held personal licenses. The rats were sacrificed before the appearance of marked clinical symptoms.

Preparation of the tumor model

C6 cells [8, 10] from the American Type Culture Collection were grown in DMEM containing 25 mM glucose and 2 mM l-glutamine (product 31966-021 from Invitrogen, Cergy Pontoise, France) to which was added 10% FBS (Invitrogen) and antibiotics. The rat glioma model was prepared as described [58]: male Wistar rats (200–230 g) were anesthetized with isoflurane and 105 C6 cells in DMEM were injected stereotaxically in the right caudate nucleus. The growth of the tumor was monitored by MRI under isofluorane anesthesia at 4.7 T (Avance III console; Bruker, Grenoble MRI Facility IRMaGe) using a T2-weighted sequence (TR/TE = 4,000/33 ms, with repetition time 4,000 ms, and echo time 33 ms [59]). When the tumor diameter was 5–7 mm (20–25 days after implantation), the rat was decapitated, the brain was rapidly removed and frozen in isopentane at −80°C, and 10 µm coronal cryosections were cut at −20°C.

Antibodies

Antibody against a conserved peptide of the E subunit of V-ATPase (SVSAEEEFNIEKLQLVEAEKKKIRQ) was prepared by Genemed Synthesis Inc. CA, USA and used at 1/500. This antibody labels V-ATPases in plants [60] and rat endothelial cells [61]. The antibody for GAPDH was a goat polyclonal NB300-320 from Novus Biologicals, used at 1/500. The antibody for Tom20 was a mouse monoclonal (Novus Biologicals H00009804_M01; called TOMM20) raised against a 146 AA recombinant protein, and used at 1/500. Immunolabeling of Tom20 has been shown to colocalize with the outer membranes of mitochondria in fish embryos [62].

Secondary antibodies were anti rabbit Alexa 488 or 633, anti-mouse Alexa 488, or 568, and anti-goat Alexa 546, all at 1/500 and from Invitrogen.

Immunofluorescence labeling

The sections were fixed for 10 min in 4% paraformaldehyde, washed and incubated for 1 h in 3% BSA at room temperature, then incubated with a pair of first antibodies in 3% BSA for 16 h at 4°C. After three rinses in PBS, the secondary antibodies were applied for 1 h at room temperature. After three more rinses, the sections were mounted in GelMount (MM, France) containing bisbenzimide trichlorohydride (Hoechst 33342, 1 µg/ml).

Imaging

Fluorescence labeled sections were observed on a Zeiss LSM 510 META. Tumors were initially located by bisbenzamide fluorescence using a xenon lamp and full field illumination. Tile scans were made with a ×10 EC Plan-Neofluor objective over areas that included a 200 µm wide strip perpendicular to the tumor rim (e.g., 1 × 6 or 3 × 5 frames). Each frame was 512 × 512 pixels and intensity was coded at 8 bits. Each tile scan was opened in ImageJ and, if necessary, the image was rotated, so that a border, well-defined by bisbenzamide, was approximately vertical, the tumor being to the right. A horizontal strip 200 µm wide and 4–5 mm long covering intra- and extratumoral tissue was selected. On the tile scan image of the second antibody, the same strip was selected in ImageJ by reference to the coordinates. The “Plot Profile” function was applied and the listed values pasted in GraphPad Prism. For each strip, the edge of the tumor was identified on the graph of the bisbenzamide labeling and the x-scale shifted so that the tumor edge was defined as x = 0. Intensity values over 1 mm or more outside the tumor were selected, pasted in a new project, and averaged. These baseline values were then used to normalize the complete profiles. The abscissae of all the profiles for each antibody were then aligned, and the profiles averaged. Ratios were calculated in Excel (Additional files 1, 2).

Statistics

Significance was calculated with Student’s t test. No outliers were excluded.

Results

GAPDH and Tom20 are upregulated throughout C6 gliomas

A section of a rat brain containing a C6 glioma stained with hematoxilin-eosin is shown in Figure 1a. Immunolabeled gliomas were visualized by fluorescence from bisbenzamide (Hoechst 33342) labeling (Figure 1b, e). Labeling of both GAPDH and Tom20 was detected outside tumors, and labeling was more intense within tumors. This is illustrated qualitatively in a section of a small tumor shown in Figure 1b–d with brightness and contrast enhanced. At higher magnification, GAPDH appeared to be localized near the peripheries of cells, while Tom20 was concentrated in small objects that could be mitochondria (Additional file 3). To determine profiles of mean upregulation across the tumor rim in several brain sections, tile scans were made and radial strips selected (Figure 1e). In unenhanced images, fluorescence was often barely perceptible to the eye, but upregulation within the tumor was apparent on intensity profiles (Figure 1f, g).
Figure 1

Upregulation of GAPDH and Tom20 in C6 gliomas. a A section of rat brain stained with hematoxilin and eosin to show a glioma produced by implantation of C6 cells in the right caudate nucleus. In this case, cells also grew in the region of the syringe needle track through the cortex. (bd). A small glioma labeled by bisbenzamide (b) and with antibodies against Tom20 (c) and GAPDH (d). The brightness and contrast have been increased. e Illustration of a strip perpendicular to the rim of a glioma (labeled with bisbenzamide) and along which intensity profiles were measured. f, g Tom20 and GAPDH fluorescence along such a strip (barely visible without enhancement). The graphs show the raw intensity values given by ImageJ.

The averages of 16 pairs of profiles are shown in Figure 2a where it is seen that labeling of both GAPDH and Tom20 increased rapidly over the first 0.2 mm into the tumors. The mean intensity relative to outside the tumor over the range 1.5–2.0 mm into the tumor was calculated for each of the 16 profiles. Over this distance, the mean upregulation of GAPDH was 1.57, SD = 0.32, N = 16, and of Tom20, 1.50 ± 0.44. The upregulation of both GAPDH and Tom20 was significant with p < 0.0001 and p = 0.0004 respectively. Mean upregulation of Tom20 from 0.2 to 2 mm was generally slightly greater than that of GAPDH. To examine this, the ratios of the upregulation Tom20/GAPDH were calculated for each pair of profiles (Additional file 1), and the mean and SEM plotted (Figure 2b). The greatest difference was over the range ≈ 0.4–0.8 mm (dashed lines in Figure 2b) where the mean ratio was 1.159, SEM = 0.001, N = 16 pairs of profiles, which is significantly greater than 1 with p < 0.0001. Even deeper into the tumor (2.0–2.5 mm) the mean increase in Tom20 labeling was statistically greater that of GAPDH, the mean ratio over 2.0–2.5 mm being 1.084 (SEM. 0.001, N = 11 profiles, p < 0.0001). These results suggest that in this sample of gliomas mitochondrial presence was, on average, upregulated slightly more than the glycolytic pathway up to at least 2.5 mm from the rim, with a peak in the ratio near the rim. There was, however, considerable variation from one profile to another (Figure 2c).
Figure 2

Averaged profiles of upreglation of Tom20 and GAPDH. a Means of 16 pairs of profiles for Tom20 and GAPDH. b The mean ratios of individual pairs of profiles, Tom20/GAPDH. The ratio is greatest in the range 0.4–0.8 mm (vertical lines). c Mean values for individual profiles over the distance 0.4–0.8 mm into the glioma.

V-ATPase upregulation

Upregulated glycolysis and mitochondrial activity suggest cell proliferation, for which acidic intracellular vacuoles are required. As expected, labeling of V-ATPase was upregulated within the gliomas (Figure 3a). When the intensity relative to outside over the distance 0.5–2.0 mm into the glioma was calculated for each profile, the mean value for the nine profiles was 1.61, SD = 0.34, p < 0.0001. GAPDH was labelled on the same sections and the ratio of V-ATPase upregulation to GAPDH upregulation for each pair of profiles was calculated and averaged (Additional File 2). V-ATPase was upregulated less than GAPDH, the mean ratio over 0.5–2.0 mm being 0.764, SD = 0.016, p < 0.0001 (Figure 2b). The sections were from gliomas different from those of Figure 2; the upregulation of GAPDH was greater and was not compared directly with upregulation of Tom20 (Figure 3c).
Figure 3

V-ATPase upregulation. a Average of 9 profiles of VATPase with SEM for each data point. N = 9. b The ratio of VATPase upregulation to GAPDH upregulation was calculated for each profile and averaged. c The double labeling for V-ATPase and GAPDH used for (a, b) was from a glioma different from those used for Figures 1, 2, and it had greater upregulation of GAPDH (red).

Discussion

Antibody labeling of GAPDH, Tom20 and V-ATPase was, on average, markedly increased relative to labeling outside the C6 gliomas, an increased level extending from the tumor rim to at least 2.5 mm into the tumor. This pattern is very different from that shown previously for NHE1, which is upregulated in a peak at the rim, and for the carbonic anhydrase, CAIX, which is not upregulated in this zone [19]. These radical differences appear to rule out the possibility that the observed profiles of antibody labeling are the result of some artifactual tumor-specific increase in the efficacy of antibody binding, or a reduction in the extracellular space fraction, rather than a true increase in protein expression.

There was considerable variation in the measured intensity of the labeling (always expressed relative to the intensity outside the glioma) from one profile to another and one glioma to another. For example, when the mean value for each profile over the distance 0.5–1 mm was calculated for the series of sections for which both GAPDH and V-ATPase were labeled, the coefficients of variation (SD/mean) for the 9 pairs of profiles were 0.229 for V-ATPase and 0.251 for GAPDH. A possible artifactual contributor to this variance is tissue distortion caused by stretching or compression of parts of sections. When the corresponding ratio V-ATPase/GAPDH was calculated, its coefficient of variation was much less, being 0.103. i.e., the ratio of expression of V-ATPase relative to expression of GAPDH is quite tightly controlled. Inspection of Figure 2b, c suggests that the same is true of Tom20 and GAPDH. These results strongly suggest that the different components of cell activity are well-coordinated in C6 gliomas. An unknown factor is how tightly the expression of GAPDH, Tom20 and V-ATPase are regulated in normal brain.

Upregulation of Tom20

The production of lactate by tumors has sometimes obscured the fact that oxygen consumption is, in most tumors, greater than in normal tissue [34, 63]. In rat gliomas, the oxygen saturation in much (or all) of the volume is as high as in normal brain tissue [64], although zones of hypoxic necrosis can develop [65]. In keeping with this expected availability of oxygen in C6 gliomas, expression of CAIX, which is upregulated by Hypoxia Inducible Factor 1 alpha (HIF1alpha; [66]) has been found not to be upregulated over at least 2 mm in from the rim [19]. It is therefore unsurprising that Tom20, a component of mitochondria, should be present, as we find.

Comparison of Tom20 and GAPDH

The metabolic pathways associated with glycolysis and with mitochondria can be programmed in either of two directions, to produce a maximum of ATP, or to produce precursor molecules for cell growth and proliferation, the latter function becoming predominant in proliferating cells [28, 67]. That both Tom20 and GAPDH were upregulated with a ratio close to 1 is reminiscent of the finding by Gullino et al. [34], in various types of tumor, that “glucose consumption and lactate elimination were in direct proportion to the oxygen utilized and a lack of oxygen blocked both of them”.

Although the upregulation of Tom20 compared to upregulation of GAPDH was greatest near the rim, Tom20 upregulation was still significantly higher than GAPDH deeper (>1 mm) into the tumor, although only by <10% (Figure 2b). Since C6 gliomas release lactate, there is presumably less pyruvate available to feed into the TCA cycle. Instead, part of the upregulation of Tom20 may be necessary to metabolize glutamine, supplied by the blood and a major entrant of the TCA cycle in cancer cells [27, 6870].

Closer to the rim (<0.8 mm), on sections in which Tom20 was compared directly with GAPDH, GAPDH expression was somewhat reduced so that there was a marked peak in the ratio Tom20/GAPDH. The peripheral location of MCT1 in cervix squamous carcinoma has led to the hypothesis that there can be net production of lactate within a tumor and that some of this is taken up close to the rim as a fuel for oxidative phosphorylation [35, 36]. A peak in MCT1 near the rim has also been reported in C6 gliomas [19]. Transfer of lactate, or other metabolic fuel, from one cell to another, is well known as a physiological phenomenon in muscle and nervous tissue [7174]. The observed excess of Tom20 over GAPDH near the rim seems to fit well with the hypothesis of lactate transfer in C6 gliomas (Figure 4).
Figure 4

Scheme summarizing the results and discussion. Compared to non-tumoral tissue, the tumor takes up more glucose (yellow arrows) and oxygen (blue arrows). Part of the mitochondrial metabolism in the rim is fuelled by lactate. NHE1 has a specific role in migrating cells. V-ATPase is present both on plasma membranes and intracellular vacuoles (pink). EMP Embden-Meyerhof Pathway.

V-ATPase

The presence of V-ATPase has been reported in several types of tumor where it subserves the handling of molecules for cell growth in intracellular vacuoles, and also contributes to the export of protons across the plasma membrane [40, 43, 44, 51, 52]. For the C6 gliomas of Figure 3a, the mean upregulation of V-ATPase expression was about 1.7 compared to normal brain, and it was tightly regulated against GAPDH (Figure 3b). In these sections, expression of GAPDH was upregulated more than V-ATPase. A possible explanation is that upregulation of glycolysis in C6 gliomas serves two functions: to support an increase in production of biomass (which requires V-ATPase) and also to produce pyruvate for ATP production (which does not require V-ATPase).

Conclusions

The upregulation of expression of V-ATPase and markers of glycolysis and mitochondria illustrate the co-ordinated programming of these engines of anabolism. This coordination extends to some stochastic spatial organization supporting the prediction that some of the fuel for oxidative phosphorylation in the tumor rim is supplied by glycolysis deeper into the tumor. The relatively simple technique we have used has obvious extensions to questions including transmembrane transport of glutamine [68, 69] and HCO3 [75].

Availability of supporting data

The data sets supporting the results of this article are included within the article and its additional files.

Abbreviations

CAIX: 

carbonic anhydrase IX

DMEM: 

Dulbecco’s modified Eagle’s medium

EMP: 

Embden-Meyerhof pathway

GAPDH: 

glyceraldehyde 3-phosphate dehydrogenase

MCT1: 

monocarboxylate cotransporter 1 (SLC16A1)

NHE1: 

sodium hydrogen exchanger 1 (SLC9A12)

Tom20: 

translocase of the mitochondrial outer membrane 20

V-ATPase: 

vacuolar H+-ATPase

Declarations

Authors’ contributions

EG implanted C6 cells, cut sections, established and used labeling protocols, participated in the design of the study and the drafting of the manuscript. RF performed C6 cell culture, participated in C6 cell implantation, and monitored glioma growth by MRI. MR provided and tested the antibody against V-ATPase, AG provided microscopy facilities. CR participated in the design of the study, and the drafting of the manuscript. JAC conceived the study, imaged and analyzed the intensity profiles and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank the staff of the animal care facility of the Grenoble Institut des Neurosciences. The Grenoble MRI facility IRMaGe was partly funded by the Agence Nationale pour la Recherche (France), program ‘Investissement d’Avenir’, grant ‘Infrastructure d’avenir en Biologie Santé’—ANR-11-INBS-0006. JAC received a Grant from the Chancellor’s Fund of Glasgow University.

Compliance with ethical guidelines

Competing interests The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Université Grenoble Alpes, IRMaGe
(2)
Inserm, US 17
(3)
CNRS, UMS 3552
(4)
CHU de Grenoble, Hopital Michallon, IRMaGe
(5)
Institute of Plant Sciences, The Volcan Center
(6)
Department of Engineering, University of Glasgow
(7)
Inserm, U 836
(8)
Institute of Infection, Immunity and Inflammation, University of Glasgow

References

  1. Tomasetti C, Vogelstein B (2015) Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347:78–81View ArticlePubMedGoogle Scholar
  2. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603View ArticlePubMed CentralPubMedGoogle Scholar
  3. Kislin KL, McDonough WS, Eschbacher JM, Armstrong BA, Berens ME (2009) NHERF-1: modulator of glioblastoma cell migration and invasion. Neoplasia 11:377–387View ArticlePubMed CentralPubMedGoogle Scholar
  4. Chicoine MR, Silbergeld DL (1995) Invading C6 glioma cells maintaining tumorigenicity. J Neurosurg 83:665–671View ArticlePubMedGoogle Scholar
  5. Chicoine MR, Silbergeld DL (1995) The in vitro motility of human gliomas increases with increasing grade of malignancy. Cancer 75:2904–2909View ArticlePubMedGoogle Scholar
  6. Guillamo JS, Lisovoski F, Christov C, Le Guerinel C, Defer GL, Peschanski M et al (2001) Migration pathways of human glioblastoma cells xenografted into the immunosuppressed rat brain. J Neurooncol 52:205–215View ArticlePubMedGoogle Scholar
  7. Nevo I, Woolard K, Cam M, Li A, Webster JD, Kotliarov Y et al (2014) Identification of molecular pathways facilitating glioma cell invasion in situ. PLoS One 9:e111783View ArticlePubMed CentralPubMedGoogle Scholar
  8. Benda P, Someda K, Messer J, Sweet WH (1971) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34:310–323View ArticlePubMedGoogle Scholar
  9. Auer RN, Del Maestro RF, Anderson R (1981) A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 8:325–331PubMedGoogle Scholar
  10. Grobben B, De Deyn PP, Slegers H (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310:257–270View ArticlePubMedGoogle Scholar
  11. Paris S, Pouyssegur J (1984) Growth factors activate the Na+/H+ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H+. J Biol Chem 259:10989–10994PubMedGoogle Scholar
  12. Cardone RA, Casavola V, Reshkin SJ (2005) The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 5:786–795View ArticlePubMedGoogle Scholar
  13. Stock C, Schwab A (2009) Protons make tumor cells move like clockwork. Pflugers Archiv 458:981–992View ArticlePubMedGoogle Scholar
  14. Stuwe L, Muller M, Fabian A, Waning J, Mally S, Noel J et al (2007) pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol 585:351–360View ArticlePubMed CentralPubMedGoogle Scholar
  15. Busco G, Cardone RA, Greco MR, Bellizzi A, Colella M, Antelmi E et al (2010) NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J. 24:3903–3915View ArticlePubMedGoogle Scholar
  16. Ludwig FT, Schwab A, Stock C (2013) The Na+/H+ -exchanger (NHE1) generates pH nanodomains at focal adhesions. J Cell Physiol 228:1351–1358View ArticlePubMedGoogle Scholar
  17. Vahle AK, Domikowsky B, Schwoppe C, Krahling H, Mally S, Schafers M et al (2014) Extracellular matrix composition and interstitial pH modulate NHE1-mediated melanoma cell motility. Int J Oncol 44:78–90PubMedGoogle Scholar
  18. Denker SP, Barber DL (2002) Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol 159:1087–1096View ArticlePubMed CentralPubMedGoogle Scholar
  19. Grillon E, Farion R, Fablet K, De Waard M, Tse CM, Donowitz M et al (2011) The spatial organization of proton and lactate transport in a rat brain tumor. PLoS One 6:e17416View ArticlePubMed CentralPubMedGoogle Scholar
  20. Gillies RJ, Liu Z, Bhujwalla Z (1994) 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267:C195–C203PubMedGoogle Scholar
  21. Reshkin SJ, Bellizzi A, Albarani V, Guerra L, Tommasino M, Paradiso A et al (2000) Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem 275:5361–5369View ArticlePubMedGoogle Scholar
  22. Webb BA, Chimenti M, Jacobson MP, Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11:671–677View ArticlePubMedGoogle Scholar
  23. Reshkin SJ, Greco MR, Cardone RA (2014) Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond B Biol Sci 369:20130100View ArticlePubMed CentralPubMedGoogle Scholar
  24. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66:5216–5223View ArticlePubMedGoogle Scholar
  25. Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3:895–904View ArticlePubMedGoogle Scholar
  26. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174View ArticlePubMedGoogle Scholar
  27. Newsholme EA, Crabtree B, Ardawi MS (1985) The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep 5:393–400View ArticlePubMedGoogle Scholar
  28. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033View ArticlePubMed CentralPubMedGoogle Scholar
  29. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D et al (2010) Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329:1492–1499View ArticlePubMedGoogle Scholar
  30. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95View ArticlePubMedGoogle Scholar
  31. Ahn CS, Metallo CM (2015) Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab 3:1–10View ArticlePubMed CentralPubMedGoogle Scholar
  32. Warburg H, Minami S (1923) Versuche an überlebenden Carcinomgewebe. Klin Woch 2:776–777View ArticleGoogle Scholar
  33. Warburg O, Wind E, Negelin E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530View ArticlePubMed CentralPubMedGoogle Scholar
  34. Gullino PM, Grantham FH, Courtney AH, Losonczy I (1967) Relationship between oxygen and glucose consumption by transplanted tumors in vivo. Cancer Res 27:1041–1052PubMedGoogle Scholar
  35. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 118:3930–3942PubMed CentralPubMedGoogle Scholar
  36. Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92:329–333View ArticlePubMedGoogle Scholar
  37. Icard P, Kafara P, Steyaert JM, Schwartz L, Lincet H (2014) The metabolic cooperation between cells in solid cancer tumors. Biochim Biophys Acta 1846:216–225PubMedGoogle Scholar
  38. Xie XS, Stone DK (1986) Isolation and reconstitution of the clathrin-coated vesicle proton translocating complex. J Biol Chem 261:2492–2495PubMedGoogle Scholar
  39. Mellman I, Fuchs R, Helenius A (1986) Acidification of the endocytic and exocytic pathways. Annu Rev Biochem 55:663–700View ArticlePubMedGoogle Scholar
  40. Hinton A, Bond S, Forgac M (2009) V-ATPase functions in normal and disease processes. Pflugers Arch 457:589–598View ArticlePubMedGoogle Scholar
  41. Moriyama Y, Nelson N (1989) H+-translocating ATPase in Golgi apparatus. Characterization as vacuolar H+-ATPase and its subunit structures. J Biol Chem 264:18445–18450PubMedGoogle Scholar
  42. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G et al (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10:51–64View ArticlePubMed CentralPubMedGoogle Scholar
  43. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ (1993) Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 265:C1015–C1029PubMedGoogle Scholar
  44. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN et al (2004) Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452View ArticlePubMedGoogle Scholar
  45. Bowman EJ, Bowman BJ (2005) V-ATPases as drug targets. J Bioenerg Biomembr 37:431–435View ArticlePubMedGoogle Scholar
  46. Fais S, De Milito A, You H, Qin W (2007) Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 67:10627–10630View ArticlePubMedGoogle Scholar
  47. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H et al (2005) The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65:6843–6849View ArticlePubMedGoogle Scholar
  48. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A (2009) V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 35:707–713View ArticlePubMedGoogle Scholar
  49. Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C et al (2010) Proton dynamics in cancer. J Transl Med. 8:57View ArticlePubMed CentralPubMedGoogle Scholar
  50. Hernandez A, Serrano-Bueno G, Perez-Castineira JR, Serrano A (2012) Intracellular proton pumps as targets in chemotherapy: V-ATPases and cancer. Curr Pharm Des 18:1383–1394View ArticlePubMedGoogle Scholar
  51. Volk C, Albert T, Kempski OS (1998) A proton-translocating H+-ATPase is involved in C6 glial pH regulation. Biochim Biophys Acta 1372:28–36View ArticlePubMedGoogle Scholar
  52. Philippe JM, Dubois JM, Rouzaire-Dubois B, Cartron PF, Vallette F, Morel N (2002) Functional expression of V-ATPases in the plasma membrane of glial cells. Glia. 37:365–373View ArticlePubMedGoogle Scholar
  53. Boidot R, Vegran F, Meulle A, Le Breton A, Dessy C, Sonveaux P et al (2012) Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res 72:939–948View ArticlePubMedGoogle Scholar
  54. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al (2006) p53 regulates mitochondrial respiration. Science 312:1650–1653View ArticlePubMedGoogle Scholar
  55. Vousden KH, Ryan KM (2009) p53 and metabolism. Nat Rev Cancer 9:691–700View ArticlePubMedGoogle Scholar
  56. Schmidt O, Pfanner N, Meisinger C (2010) Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol 11:655–667View ArticlePubMedGoogle Scholar
  57. Qiu J, Wenz LS, Zerbes RM, Oeljeklaus S, Bohnert M, Stroud DA et al (2013) Coupling of mitochondrial import and export translocases by receptor-mediated supercomplex formation. Cell 154:596–608View ArticlePubMedGoogle Scholar
  58. Julien C, Payen JF, Tropres I, Farion R, Grillon E, Montigon O et al (2004) Assessment of vascular reactivity in rat brain glioma by measuring regional blood volume during graded hypoxic hypoxia. Br J Cancer 91:374–380PubMed CentralPubMedGoogle Scholar
  59. Coquery N, Pannetier N, Farion R, Herbette A, Azurmendi L, Clarencon D et al (2012) Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of glioblastoma. PLoS One 7:e40567View ArticlePubMed CentralPubMedGoogle Scholar
  60. Reuveni M, Evenor D, Artzi B, Perl A, Erner Y (2001) Decrease in vacuolar pH during petunia flower opening is reflected in the activity of tonoplast H+-ATPase. J Plant Physiol 158:991–998View ArticleGoogle Scholar
  61. Sennoune SR, Martinez-Zaguilan R (2007) Plasmalemmal vacuolar H+-ATPases in angiogenesis, diabetes and cancer. J Bioenerg Biomembr 39:427–433View ArticlePubMedGoogle Scholar
  62. Yuan Y, Li M, Hong N, Hong Y (2014) Correlative light and electron microscopic analyses of mitochondrial distribution in blastomeres of early fish embryos. FASEB J 28:577–585View ArticlePubMedGoogle Scholar
  63. Weinhouse S (1976) The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 87:115–126View ArticlePubMedGoogle Scholar
  64. Christen T, Bouzat P, Pannetier N, Coquery N, Moisan A, Lemasson B et al (2014) Tissue oxygen saturation mapping with magnetic resonance imaging. J Cereb Blood Flow Metab 34:1550–1557View ArticlePubMedGoogle Scholar
  65. Zoula S, Rijken PF, Peters JP, Farion R, Van der Sanden BP, Van der Kogel AJ et al (2003) Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. Br J Cancer 88:1439–1444View ArticlePubMed CentralPubMedGoogle Scholar
  66. Jiang BH, Semenza GL, Bauer C, Marti HH (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271:C1172–C1180PubMedGoogle Scholar
  67. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20View ArticlePubMedGoogle Scholar
  68. Reitzer LJ, Wice BM, Kennell D (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254:2669–2676PubMedGoogle Scholar
  69. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350View ArticlePubMed CentralPubMedGoogle Scholar
  70. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T et al (2013) Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol 9:712View ArticlePubMed CentralPubMedGoogle Scholar
  71. Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343(Pt 2):281–299View ArticlePubMed CentralPubMedGoogle Scholar
  72. Poitry-Yamate CL, Poitry S, Tsacopoulos M (1995) Lactate released by Muller glial cells is metabolized by photoreceptors from mammalian retina. J Neurosci 15:5179–5191PubMedGoogle Scholar
  73. Vega C, Martiel JL, Drouhault D, Burckhart MF, Coles JA (2003) Uptake of locally applied deoxyglucose, glucose and lactate by axons and Schwann cells of rat vagus nerve. J Physiol 546:551–564View ArticlePubMed CentralPubMedGoogle Scholar
  74. Coles JA, Martiel JL, Laskowska K (2008) A glia-neuron alanine/ammonium shuttle is central to energy metabolism in bee retina. J Physiol 586:2077–2091View ArticlePubMed CentralPubMedGoogle Scholar
  75. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL (2010) New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29:6509–6521View ArticlePubMedGoogle Scholar

Copyright

© Grillon et al. 2015

Advertisement